PerCP/Cyanine5.5 anti-mouse CD80 Antibody

Product Details

Verified Reactivity

Mouse

Reported Reactivity

Dog

Antibody Type

Monoclonal

Host Species

Armenian Hamster

Immunogen

CHO cell line transfected with mouse B7 (CD80)

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation², in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells^2-4, and immunohistochemical staining of acetone-fixed frozen sections^1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
5. Ma XT, et al. 2006. Cancer Res. 66:1169.
6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed

Product Citations

1. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
2. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
3. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
4. Luger R, et al. 2013. PLoS One. 8:e54879. PubMed
5. Taylor J, et al. 2012. J Exp Med. 209:2065. PubMed
6. Sepe JJ, et al. 2022. JACC Basic Transl Sci. 7:915. PubMed
7. Li C, et al. 2022. Theranostics. 12:4581. PubMed
8. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
9. Pack AD, et al. 2021. Cell Reports. 36(8):109586. PubMed
10. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
11. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
12. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
13. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
14. Khiew SH, et al. 2020. J Clin Invest. 130:3453. PubMed
15. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
16. Alves C, et al. 2015. PLoS One. 10: 0142972. PubMed
17. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
18. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
19. Li H, et al. 2020. Nature. 584:274. PubMed
20. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
21. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
22. Argüello RJ, et al. 2018. J Cell Sci. 131:jcs214346. PubMed
23. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
24. Zhao L, et al. 2021. STAR Protocols. 2(3):100732. PubMed
25. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
26. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
27. Liu P, et al. 2020. Mol Cell. 748:77. PubMed
28. Barbet G, et al. 2018. Immunity. 48:584. PubMed
29. Darling R, et al. 2020. Int J Nanomedicine. 5.19375. PubMed
30. Lopes N, et al. 2022. Elife. 11:. PubMed
31. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
32. Wallner S, et al. 2013. PLoS One. 8:65178. PubMed
33. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
34. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed

RRID

AB_893406 (BioLegend Cat. No. 104721)
AB_2291392 (BioLegend Cat. No. 104722)

Antigen Details

Structure

Ig superfamily, 60 kD

Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function

T cell costimulation

Ligand/Receptor

CD28 (stimulatory), CD152(CTLA4) (inhibitory)

Cell Type

B cells, Dendritic cells, Macrophages, T cells, Tregs

Biology Area

Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers

Molecular Family

CD Molecules, Immune Checkpoint Receptors

Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID

12519 View all products for this Gene ID

UniProt

View information about CD80 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis